Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309665 | 0.92 | EGLN1 (0.38) | EGLN1HSD11B1TRPV4HCRTR1HCRTR2 | |
| SCHEMBL308959 | 0.92 | HSD11B1 (0.38) | EGLN1HSD11B1TRPV4HCRTR1HCRTR2 | |
| SCHEMBL309678 | 0.88 | IDH1 (0.45) | EGLN1GAAIDH1 | |
| SCHEMBL13510913 | 0.86 | EGLN1 (0.40) | EGLN1TRPV4GAAPDK1PDK2 | |
| SCHEMBL2840624 | 0.82 | EGLN1 (0.46) | EGLN1TRPV4PDK1PDK2PDK3 | |
| SCHEMBL10042207 | 0.82 | CCR6 (0.44) | HSD11B1 | |
| SCHEMBL2833231 | 0.79 | EGLN1 (0.39) | EGLN1TRPV4GAAHCRTR1HCRTR2 | |
| SCHEMBL1429552 | 0.79 | EGLN1 (0.51) | EGLN1PDK1PDK2PDK3PDK4 | |
| SCHEMBL2834502 | 0.79 | EGLN1 (0.51) | EGLN1PDK1PDK2PDK3PDK4 | |
| SCHEMBL2836332 | 0.78 | TRPV4 (0.42) | EGLN1HSD11B1TRPV4GAAPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313413-B1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | CONVERGENCE PHARMACEUTICALS (GB) | 2012-05-16 | — | — | EP | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | EGLN1 3078/4885HSD11B1 4779/4885PDE2A 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.